This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Sanofi branded clouded background image

Latest Education

Education1 Jun 2024

EBMT 2024: Expanding the cGvHD treatment paradigm with novel therapeutics

Education24 May 2024

InTen Nurse Forum - ACCEND Framework

For nurses and allied healthcare professionals with an interest in chronic GvHD

Education24 May 2024

InTen Nurse Forum: What is chronic GvHD?

For nurses and allied healthcare professionals with an interest in chronic GvHD

Sohail Akhtar - 29.03.24

Education17 Apr 2024

Diabetes UK 2024: Sustainably scripting tomorrow with Sanofi's Planet Cares Programme and Pen Recycling pilot

Slides and recording of Diabetes UK 2024 - in collaboration with Diabetes Specialist Nurse Forum UK

Sohail Akhtar - 29.03.24

Education17 Apr 2024

Diabetes UK 2024: Connecting the Dots: Benefits of pen connectivity for people living with diabetes

Slides and recording of Diabetes UK 2024 - in collaboration with Diabetes Specialist Nurse Forum UK

Education23 Oct 2023

The Continuing Role of Secondary Care in Lipid Optimisation Post-ACS

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

Education23 Oct 2023

What Insulins Do I Need In My Toolbox To Support People With Type 2 Diabetes

Lantus® (insulin glargine 100 units/mL) Prescribing Information UK Toujeo® (insulin glargine 300 units/mL) Prescribing Information UK

Education23 Oct 2023

Implementing Artificial Intelligence to Risk Stratify, Manage and Refer Patients

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

Education23 Oct 2023

New Approaches and Innovation in Lipid Services – Strengthening the Relationship between Primary and Secondary Care

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

MAT-XU-2305049 (v2.0) Date of preparation: February 2024